Xencor Revenue
Biotechnology Research • 
Pasadena, California, United States • 201-500 Employees
Xencor revenue & valuation
| Annual revenue | $147,000,000 |
| Revenue per employee | $509,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $470,200,000 |
| Total funding | $226,300,000 |
Key Contacts at Xencor
Marisa Stubbs
Associate Director, Talent Acquisition
Engie Salama
Associate Director
Bryan P.
Associate Director, Cmc Operations
Kristy Colella
Director, Clinical Data Management
Juhi Firdos
Director
Raul Acosta
Senior Director, Facilities & Engineering
Shayan Yousufzai
Director, R&D Finance
Shelley Belouski
Executive Director, Nonclinical & Bioanalytical Development
Sudipta Majumdar
Director, Analytical Sciences Cmc
Mahrukh Yasin
Director Of Business Development
Company overview
| Headquarters | 465 N Halstead St, Suite 200, Pasadena, California 91107, US |
| Phone number | +16263055900 |
| Website | |
| SIC | 283 |
| Keywords | Biotechnology, Oncology, Drug Development, Autoimmune Disease, Cytokines, Protein Engineering, Bispecific Antibodies, Antibody Drugs |
| Founded | 1997 |
| Employees | 201-500 |
| Socials |
Xencor Email Formats
Xencor uses 3 email formats. The most common is {first name}{last name} (e.g., johndoe@xencor.com), used 52.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@xencor.com | 52.9% |
{first initial}{last name} | jdoe@xencor.com | 41.9% |
{last name}{last name} | doedoe@xencor.com | 3.1% |
About Xencor
Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Xencor has 144 employees across 14 departments.
Departments
Number of employees
Funding Data
Explore Xencor's funding history, including investment rounds, total capital raised, and key backers.
Xencor Tech Stack
Discover the technologies and tools that power Xencor's digital infrastructure, from frameworks to analytics platforms.
CDN
JavaScript libraries
JavaScript libraries
JavaScript libraries
JavaScript graphics
CDN
JavaScript libraries
Font scripts
JavaScript libraries
Webmail
JavaScript libraries
Miscellaneous
India
Frequently asked questions
4.8
40,000 users
